Clinical and Prognostic Impact of the Warburg Effect in Esophageal Carcinoma: Monocarboxylate Transporters as Candidates for Therapeutic Targeting

2.

Short

MW

,

Burgers

KG

,

Fry

VT

.

Esophageal cancer

.

Am Fam Physician

.

2017

;

95

(

1

):

22

–

8

.

3.

Cummings

D

,

Wong

J

,

Palm

R

,

Hoffe

S

,

Almhanna

K

,

Vignesh

S

.

Epidemiology, diagnosis, staging and multimodal therapy of esophageal and gastric tumors

.

Cancers

.

2021

;

13

(

3

):

582

.

4.

Siegel

RL

,

Miller

KD

,

Fuchs

HE

,

Jemal

A

.

Cancer statistics, 2021

.

CA Cancer J Clin

.

2021

;

71

(

1

):

7

–

33

.

5.

Mao

C

,

Zeng

X

,

Zhang

C

,

Yang

Y

,

Xiao

X

,

Luan

S

, .

Mechanisms of pharmaceutical therapy and drug resistance in esophageal cancer

.

Front Cell Dev Biol

.

2021

;

9

:

612451

.

6.

DeBerardinis

RJ

,

Chandel

NS

.

We need to talk about the Warburg effect

.

Nat Metab

.

2020

;

2

(

2

):

127

–

9

.

7.

Warburg

O

.

On the origin of cancer cells

.

Science

.

1956

;

123

(

3191

):

309

–

14

.

8.

Hanahan

D

,

Weinberg

RA

.

Hallmarks of cancer: the next generation

.

Cell

.

2011

;

144

(

5

):

646

–

74

.

9.

Baltazar

F

,

Afonso

J

,

Costa

M

,

Granja

S

.

Lactate beyond a waste metabolite: metabolic affairs and signaling in malignancy

.

Front Oncol

.

2020

;

10

(

231

):

231

.

10.

Pereira-Nunes

A

,

Afonso

J

,

Granja

S

,

Baltazar

F

.

Lactate and lactate transporters as key players in the maintenance of the Warburg effect

. In:

Serpa

J

, editor.

Tumor microenvironment: the main driver of metabolic adaptation

.

Cham

:

Springer International Publishing

;

2020

. p.

51

–

74

.

11.

Parks

SK

,

Chiche

J

,

Pouyssegur

J

.

Disrupting proton dynamics and energy metabolism for cancer therapy

.

Nat Rev Cancer

.

2013

;

13

(

9

):

611

–

23

.

12.

Parks

SK

,

Cormerais

Y

,

Pouyssegur

J

.

Hypoxia and cellular metabolism in tumour pathophysiology

.

J Physiol

.

2017

;

595

(

8

):

2439

–

50

.

13.

Parks

SK

,

Mueller-Klieser

W

,

Pouysségur

J

.

Lactate and acidity in the cancer microenvironment

.

Annu Rev Cancer Biol

.

2020

;

4

(

1

):

141

–

58

.

14.

Marchiq

I

,

Pouyssegur

J

.

Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters

.

J Mol Med

.

2016

;

94

(

2

):

155

–

71

.

15.

Belisario

DC

,

Kopecka

J

,

Pasino

M

,

Akman

M

,

De Smaele

E

,

Donadelli

M

, .

Hypoxia dictates metabolic rewiring of tumors: implications for chemoresistance

.

Cells

.

2020

;

9

(

12

):

2598

.

16.

Wigerup

C

,

Pahlman

S

,

Bexell

D

.

Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer

.

Pharmacol Ther

.

2016

;

164

:

152

–

69

.

17.

Jun

JC

,

Rathore

A

,

Younas

H

,

Gilkes

D

,

Polotsky

VY

.

Hypoxia-inducible factors and cancer

.

Curr Sleep Med Rep

.

2017

;

3

(

1

):

1

–

10

.

18.

Chen

C

,

Pore

N

,

Behrooz

A

,

Ismail-Beigi

F

,

Maity

A

.

Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia

.

J Biol Chem

.

2001

;

276

(

12

):

9519

–

25

.

19.

Marin-Hernandez

A

,

Gallardo-Perez

JC

,

Ralph

SJ

,

Rodriguez-Enriquez

S

,

Moreno-Sanchez

R

.

HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms

.

Mini Rev Med Chem

.

2009

;

9

(

9

):

1084

–

101

.

20.

Semenza

GL

.

HIF-1: upstream and downstream of cancer metabolism

.

Curr Opin Genet Dev

.

2010

;

20

(

1

):

51

–

6

.

21.

Ancey

PB

,

Contat

C

,

Meylan

E

.

Glucose transporters in cancer: from tumor cells to the tumor microenvironment

.

FEBS J

.

2018

;

285

(

16

):

2926

–

43

.

22.

Pastorekova

S

,

Gillies

RJ

.

The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond

.

Cancer Metastasis Rev

.

2019

;

38

(

1–2

):

65

–

77

.

23.

Payen

VL

,

Mina

E

,

Van Hee

VF

,

Porporato

PE

,

Sonveaux

P

.

Monocarboxylate transporters in cancer

.

Mol Metab

.

2020

;

33

:

48

–

66

.

24.

Abdel-Wahab

AF

,

Mahmoud

W

,

Al-Harizy

RM

.

Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy

.

Pharmacol Res

.

2019

;

150

:

104511

.

25.

Lin

X

,

Xiao

Z

,

Chen

T

,

Liang

SH

,

Guo

H

.

Glucose metabolism on tumor plasticity, diagnosis, and treatment

.

Front Oncol

.

2020

;

10

:

317

.

26.

Zhu

X

,

Wang

K

,

Liu

G

,

Wang

Y

,

Xu

J

,

Liu

L

, .

Metabolic perturbation and potential markers in patients with esophageal cancer

.

Gastroenterol Res Pract

.

2017

;

2017

:

5469597

.

27.

Yu

M

,

Chen

S

,

Hong

W

,

Gu

Y

,

Huang

B

,

Lin

Y

, .

Prognostic role of glycolysis for cancer outcome: evidence from 86 studies

.

J Cancer Res Clin Oncol

.

2019

;

145

(

4

):

967

–

99

.

28.

Mao

X

,

Zhu

H

,

Luo

D

,

Ye

L

,

Yin

H

,

Zhang

J

, .

Capsaicin inhibits glycolysis in esophageal squamous cell carcinoma by regulating hexokinase2 expression

.

Mol Med Rep

.

2018

;

17

(

4

):

6116

–

21

.

29.

Li

S

,

Huang

P

,

Gan

J

,

Ling

X

,

Du

X

,

Liao

Y

, .

Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2

.

Eur J Pharmacol

.

2019

;

854

:

232

–

9

.

30.

Deng

X

,

Zhao

J

,

Qu

L

,

Duan

Z

,

Fu

R

,

Zhu

C

, .

Ginsenoside Rh4 suppresses aerobic glycolysis and the expression of PD-L1 via targeting AKT in esophageal cancer

.

Biochem Pharmacol

.

2020

;

178

:

114038

.

31.

Li

F

,

Zhang

Z

,

Wang

P

,

Wen

P

,

Xu

Q

,

Wang

Y

, .

ALC1 knockdown enhances cisplatin cytotoxicity of esophageal squamous cell carcinoma cells by inhibition of glycolysis through PI3K/Akt pathway

.

Life Sci

.

2019

;

232

:

116679

.

32.

Sawayama

H

,

Ogata

Y

,

Ishimoto

T

,

Mima

K

,

Hiyoshi

Y

,

Iwatsuki

M

, .

Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer

.

Cancer Sci

.

2019

;

110

(

5

):

1705

–

14

.

33.

Rice

TW

,

Blackstone

EH

,

Rusch

VW

.

7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction

.

Ann Surg Oncol

.

2010

;

17

(

7

):

1721

–

4

.

34.

Wu

J

,

Chen

QX

.

Prognostic and predictive significance of tumor length in patients with esophageal squamous cell carcinoma undergoing radical resection

.

BMC Cancer

.

2016

;

16

:

394

.

35.

He

Y

,

Liang

D

,

Du

L

,

Guo

T

,

Liu

Y

,

Sun

X

, .

Clinical characteristics and survival of 5283 esophageal cancer patients: a multicenter study from eighteen hospitals across six regions in China

.

Cancer Commun

.

2020

;

40

(

10

):

531

–

44

.

36.

Yukawa

N

,

Aoyama

T

,

Tamagawa

H

,

Tamagawa

A

,

Atsumi

Y

,

Kawahara

S

, .

The lymph node ratio is an independent prognostic factor in esophageal cancer patients who receive curative surgery

.

In Vivo

.

2020

;

34

(

4

):

2087

–

93

.

37.

Huhta

H

,

Helminen

O

,

Palomaki

S

,

Kauppila

JH

,

Saarnio

J

,

Lehenkari

PP

, .

Intratumoral lactate metabolism in Barrett’s esophagus and adenocarcinoma

.

Oncotarget

.

2017

;

8

(

14

):

22894

–

902

.

38.

Muramatsu

T

.

Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners

.

J Biochem

.

2016

;

159

(

5

):

481

–

90

.

39.

Xin

X

,

Zeng

X

,

Gu

H

,

Li

M

,

Tan

H

,

Jin

Z

, .

CD147/EMMPRIN overexpression and prognosis in cancer: a systematic review and meta-analysis

.

Sci Rep

.

2016

;

6

(

1

):

32804

.

40.

Landras

A

,

Reger de Moura

C

,

Jouenne

F

,

Lebbe

C

,

Menashi

S

,

Mourah

S

.

CD147 is a promising target of tumor progression and a prognostic biomarker

.

Cancers

.

2019

;

11

(

11

):

1803

.

41.

Li

H

,

Jiang

C

,

Wu

D

,

Shi

S

,

Liao

M

,

Wang

J

, .

The prognostic and clinicopathologic characteristics of CD147 and esophagus cancer: a meta-analysis

.

PLoS One

.

2017

;

12

(

7

):

e0180271

.

42.

Zhang

X

,

Xu

L

,

Shen

J

,

Cao

B

,

Cheng

T

,

Zhao

T

, .

Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum

.

Biochim Biophys Acta

.

2013

;

1832

(

8

):

1207

–

16

.

43.

Ye

W

,

Lin

Y

,

Bezabeh

T

,

Ma

C

,

Liang

J

,

Zhao

J

, .

¹H NMR-based metabolomics of paired esophageal tumor tissues and serum samples identifies specific serum biomarkers for esophageal cancer

.

NMR Biomed

.

2021

;

34

(

6

):

e4505

.

44.

Miranda-Goncalves

V

,

Honavar

M

,

Pinheiro

C

,

Martinho

O

,

Pires

MM

,

Pinheiro

C

, .

Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets

.

Neuro Oncol

.

2013

;

15

(

2

):

172

–

88

.

45.

Afonso

J

,

Santos

LL

,

Miranda-Goncalves

V

,

Morais

A

,

Amaro

T

,

Longatto-Filho

A

, .

CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance

.

Mol Carcinog

.

2015

;

54

(

11

):

1451

–

66

.

46.

Chen

X

,

Chen

X

,

Liu

F

,

Yuan

Q

,

Zhang

K

,

Zhou

W

, .

Monocarboxylate transporter 1 is an independent prognostic factor in esophageal squamous cell carcinoma

.

Oncol Rep

.

2019

;

41

(

4

):

2529

–

39

.

47.

Zhang

T

,

Li

H

,

Zhang

Y

,

Wang

P

,

Bian

H

,

Chen

ZN

.

Expression of proteins associated with epithelial-mesenchymal transition in esophageal squamous cell carcinoma

.

Oncol Lett

.

2018

;

15

(

3

):

3042

–

8

.

48.

Wang

M

,

Zhang

S

,

Sun

Q

,

Yang

X

,

Wang

Y

,

Shang

R

, .

Dual effects of an anti-CD147 antibody for esophageal cancer therapy

.

Cancer Biol Ther

.

2019

;

20

(

12

):

1443

–

52

.

49.

Cheng

B

,

Chen

X

,

Li

Y

,

Huang

X

,

Yu

J

.

Prognostic value of monocarboxylate transporter 4 in patients with esophageal squamous cell carcinoma

.

Oncol Rep

.

2018

;

40

(

5

):

2906

–

15

.

50.

Halestrap

AP

,

Meredith

D

.

The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond

.

Pflugers Arch

.

2004

;

447

(

5

):

619

–

28

.

51.

Halestrap

AP

.

The SLC16 gene family - structure, role and regulation in health and disease

.

Mol Aspects Med

.

2013

;

34

(

2–3

):

337

–

49

.

52.

Pereira-Nunes

A

,

Afonso

J

,

Granja

S

,

Baltazar

F

.

Lactate and lactate transporters as key players in the maintenance of the Warburg effect

.

Adv Exp Med Biol

.

2020

;

1219

:

51

–

74

.

. https://doi.org/10.1186/1471-2407-11-312.

53.

Pertega-Gomes

N

,

Vizcaino

JR

,

Miranda-Goncalves

V

,

Pinheiro

C

,

Silva

J

,

Pereira

H

, .

Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer

.

BMC Cancer

.

2011

;

11

:

312

54.

Alves

VA

,

Pinheiro

C

,

Morais-Santos

F

,

Felipe-Silva

A

,

Longatto-Filho

A

,

Baltazar

F

.

Characterization of monocarboxylate transporter activity in hepatocellular carcinoma

.

World J Gastroenterol

.

2014

;

20

(

33

):

11780

–

7

.

55.

Doyen

J

,

Trastour

C

,

Ettore

F

,

Peyrottes

I

,

Toussant

N

,

Gal

J

, .

Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome

.

Biochem Biophys Res Commun

.

2014

;

451

(

1

):

54

–

61

.

56.

Mariette

C

,

Finzi

L

,

Piessen

G

,

Van Seuningen

I

,

Triboulet

JP

.

Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma

.

World J Surg

.

2005

;

29

(

1

):

39

–

45

.

57.

Lagisetty

KH

,

Beer

DG

,

Chang

AC

.

Squamous cell carcinomas and adenocarcinomas of the esophagus: one treatment does not rule them all

.

J Thorac Cardiovasc Surg

.

2017

;

154

(

4

):

1446

–

7

.

58.

Yang

J

,

Liu

X

,

Cao

S

,

Dong

X

,

Rao

S

,

Cai

K

.

Understanding esophageal cancer: the challenges and opportunities for the next decade

.

Front Oncol

.

2020

;

10

:

1727

.

59.

The Cancer Genome Atlas Research Network

.

Integrated genomic characterization of oesophageal carcinoma

.

Nature

.

2017

;

541

(

7636

):

169

–

75

.

60.

Dotto

GP

,

Rustgi

AK

.

Squamous cell cancers: a unified perspective on biology and genetics

.

Cancer Cell

.

2016

;

29

(

5

):

622

–

37

.

61.

Choe

JH

,

Mazambani

S

,

Kim

TH

,

Kim

JW

.

Oxidative stress and the intersection of oncogenic signaling and metabolism in squamous cell carcinomas

.

Cells

.

2021

;

10

(

3

):

606

.

62.

Sanchez-Danes

A

,

Blanpain

C

.

Deciphering the cells of origin of squamous cell carcinomas

.

Nat Rev Cancer

.

2018

;

18

(

9

):

549

–

61

.

63.

Zhang

X

,

Lan

L

,

Niu

L

,

Lu

J

,

Li

C

,

Guo

M

, .

Oxidative stress regulates cellular bioenergetics in esophageal squamous cell carcinoma cell

.

Biosci Rep

.

2017

;

37

(

6

):

BSR20171006

.

64.

Hsieh

MH

,

Choe

JH

,

Gadhvi

J

,

Kim

YJ

,

Arguez

MA

,

Palmer

M

, .

p63 and SOX2 dictate glucose reliance and metabolic vulnerabilities in squamous cell carcinomas

.

Cell Rep

.

2019

;

28

(

7

):

1860

–

78.e9

.

65.

Pragallapati

S

,

Manyam

R

.

Glucose transporter 1 in health and disease

.

J Oral Maxillofac Pathol

.

2019

;

23

(

3

):

443

–

9

.

66.

Yu

M

,

Yongzhi

H

,

Chen

S

,

Luo

X

,

Lin

Y

,

Zhou

Y

, .

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis

.

Oncotarget

.

2017

;

8

(

26

):

43356

–

67

.

67.

Tohma

T

,

Okazumi

S

,

Makino

H

,

Cho

A

,

Mochizuki

R

,

Shuto

K

, .

Overexpression of glucose transporter 1 in esophageal squamous cell carcinomas: a marker for poor prognosis

.

Dis Esophagus

.

2005

;

18

(

3

):

185

–

9

.

68.

Hiyoshi

Y

,

Watanabe

M

,

Imamura

Y

,

Nagai

Y

,

Baba

Y

,

Yoshida

N

, .

The relationship between the glucose transporter type 1 expression and F-fluorodeoxyglucose uptake in esophageal squamous cell carcinoma

.

Oncology

.

2009

;

76

(

4

):

286

–

92

.

69.

Chiba

I

,

Ogawa

K

,

Morioka

T

,

Shimoji

H

,

Sunagawa

N

,

Iraha

S

, .

Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy

.

Oncol Lett

.

2011

;

2

(

1

):

21

–

8

.

70.

Sawayama

H

,

Ishimoto

T

,

Watanabe

M

,

Yoshida

N

,

Baba

Y

,

Sugihara

H

, .

High expression of glucose transporter 1 on primary lesions of esophageal squamous cell carcinoma is associated with hematogenous recurrence

.

Ann Surg Oncol

.

2014

;

21

(

5

):

1756

–

62

.

71.

Zhou

YX

,

Zhou

KM

,

Liu

Q

,

Wang

H

,

Wang

W

,

Shi

Y

, .

The effect of Glut1 and c-myc on prognosis in esophageal squamous cell carcinoma of Kazakh and Han patients

.

Future Oncol

.

2018

;

14

(

18

):

1801

–

15

.

72.

Liu

XS

,

Gao

Y

,

Wu

LB

,

Wan

HB

,

Yan

P

,

Jin

Y

, .

Comprehensive analysis of GLUT1 immune infiltrates and ceRNA network in human esophageal carcinoma

.

Front Oncol

.

2021

;

11

:

665388

.

73.

Rice

TW

,

Ishwaran

H

,

Blackstone

EH

.

Oesophageal cancer: location, location, location

.

Eur J Cardiothorac Surg

.

2015

;

48

(

2

):

194

–

5

.

74.

Koukourakis

MI

,

Giatromanolaki

A

,

Bougioukas

G

,

Sivridis

E

.

Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma

.

Cancer Biol Ther

.

2007

;

6

(

9

):

1476

–

9

.

75.

Mathupala

SP

,

Parajuli

P

,

Sloan

AE

.

Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study

.

Neurosurgery

.

2004

;

55

(

6

):

1410

–

9

; discussion 1419. https://doi.org/10.1227/01.neu.0000143034.62913.59.

76.

Pinheiro

C

,

Longatto-Filho

A

,

Scapulatempo

C

,

Ferreira

L

,

Martins

S

,

Pellerin

L

, .

Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas

.

Virchows Arch

.

2008

;

452

(

2

):

139

–

46

.

77.

Jung

DE

,

Kim

JM

,

Kim

C

,

Song

SY

.

Embigin is overexpressed in pancreatic ductal adenocarcinoma and regulates cell motility through epithelial to mesenchymal transition via the TGF-beta pathway

.

Mol Carcinog

.

2016

;

55

(

5

):

633

–

45

.

78.

Pertega-Gomes

N

,

Vizcaino

JR

,

Gouveia

C

,

Jeronimo

C

,

Henrique

RM

,

Lopes

C

, .

Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer

.

Prostate

.

2013

;

73

(

7

):

763

–

9

.

79.

Pinheiro

C

,

Granja

S

,

Longatto-Filho

A

,

Faria

AM

,

Fragoso

MCBV

,

Lovisolo

SM

, .

Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors

.

Oncotarget

.

2015

;

6

(

42

):

44403

–

21

.

80.

Roberts

DJ

,

Miyamoto

S

.

Hexokinase II integrates energy metabolism and cellular protection: akting on mitochondria and TORCing to autophagy

.

Cell Death Differ

.

2015

;

22

(

2

):

364

–

57

.

81.

Ciscato

F

,

Ferrone

L

,

Masgras

I

,

Laquatra

C

,

Rasola

A

.

Hexokinase 2 in cancer: a prima donna playing multiple characters

.

Int J Mol Sci

.

2021

:

22

(

9

).

82.

Liu

Y

,

Wu

K

,

Shi

L

,

Xiang

F

,

Tao

K

,

Wang

G

.

Prognostic significance of the metabolic marker hexokinase-2 in various solid tumors: a meta-analysis

.

PloS one

.

2016

;

11

(

11

):

e0166230

.

83.

Wu

J

,

Hu

L

,

Wu

F

,

Zou

L

,

He

T

.

Poor prognosis of hexokinase 2 overexpression in solid tumors of digestive system: a meta-analysis

.

Oncotarget

.

2017

;

8

(

19

):

32332

–

44

.

84.

Li

W

,

Xu

Z

,

Hong

J

,

Xu

Y

.

Expression patterns of three regulation enzymes in glycolysis in esophageal squamous cell carcinoma: association with survival

.

Med Oncol

.

2014

;

31

(

9

):

118

.

85.

Zhang

S

,

Wang

D

,

Huang

J

,

Hu

Y

,

Xu

Y

.

Application of capsaicin as a potential new therapeutic drug in human cancers

.

J Clin Pharm Ther

.

2020

;

45

(

1

):

16

–

28

.

86.

Lynam-Lennon

N

,

Connaughton

R

,

Carr

E

,

Mongan

AM

,

O’Farrell

NJ

,

Porter

RK

, .

Excess visceral adiposity induces alterations in mitochondrial function and energy metabolism in esophageal adenocarcinoma

.

BMC Cancer

.

2014

;

14

:

907

.

87.

Ho

N

,

Coomber

BL

.

Hexokinase II expression is correlated with colorectal cancer prognosis

.

Cancer Treat Commun

.

2016

;

6

:

11

–

6

.

88.

Lyshchik

A

,

Higashi

T

,

Hara

T

,

Nakamoto

Y

,

Fujimoto

K

,

Doi

R

, .

Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer

.

Cancer Invest

.

2007

;

25

(

3

):

154

–

62

.

89.

Chen

X

,

Song

E

.

Turning foes to friends: targeting cancer-associated fibroblasts

.

Nat Rev Drug Discov

.

2019

;

18

(

2

):

99

–

115

.

90.

Saunier

E

,

Benelli

C

,

Bortoli

S

.

The pyruvate dehydrogenase complex in cancer: an old metabolic gatekeeper regulated by new pathways and pharmacological agents

.

Int J Cancer

.

2016

;

138

(

4

):

809

–

17

.

91.

Atas

E

,

Oberhuber

M

,

Kenner

L

.

The implications of PDK1-4 on tumor energy metabolism, aggressiveness and therapy resistance

.

Front Oncol

.

2020

;

10

:

583217

.

92.

Zhong

Y

,

Huang

R

,

Li

X

,

Xu

R

,

Zhou

F

,

Wang

J

, .

Decreased expression of PDHE1α predicts worse clinical outcome in esophageal squamous cell carcinoma

.

Anticancer Res

.

2015

;

35

(

10

):

5533

–

8

.

93.

Liu

L

,

Cao

J

,

Zhao

J

,

Li

X

,

Suo

Z

,

Li

H

.

PDHA1 gene knockout in human esophageal squamous cancer cells resulted in greater Warburg effect and aggressive features in vitro and in vivo

.

Onco Targets Ther

.

2019

;

12

:

9899

–

913

.

94.

Yao

F

,

Zhao

T

,

Zhong

C

,

Zhu

J

,

Zhao

H

.

LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma

.

Tumour Biol

.

2013

;

34

(

1

):

25

–

31

.

95.

Feng

Y

,

Xiong

Y

,

Qiao

T

,

Li

X

,

Jia

L

,

Han

Y

.

Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy

.

Cancer Med

.

2018

;

7

(

12

):

6124

–

36

.

96.

Lv

J

,

Zhou

Z

,

Wang

J

,

Yu

H

,

Lu

H

,

Yuan

B

, .

Prognostic value of lactate dehydrogenase expression in different cancers: a meta-analysis

.

Am J Med Sci

.

2019

;

358

(

6

):

412

–

21

.

97.

Li

R

,

Li

H

,

Wang

S

,

Ma

J

,

Zhang

Y

,

Ye

J

, .

Novel prognostic value of nuclear lactate dehydrogenase-A in esophageal squamous cell carcinoma

.

Int J Clin Exp Pathol

.

2016

;

9

(

3

):

3708

–

16

.

98.

Liu

Y

,

Guo

JZ

,

Liu

Y

,

Wang

K

,

Ding

W

,

Wang

H

, .

Nuclear lactate dehydrogenase A senses ROS to produce alpha-hydroxybutyrate for HPV-induced cervical tumor growth

.

Nat Commun

.

2018

;

9

(

1

):

4429

.

99.

Driessen

A

,

Landuyt

W

,

Pastorekova

S

,

Moons

J

,

Goethals

L

,

Haustermans

K

, .

Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas

.

Ann Surg

.

2006

;

243

(

3

):

334

–

40

.

100.

Tanaka

N

,

Kato

H

,

Inose

T

,

Kimura

H

,

Faried

A

,

Sohda

M

, .

Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma

.

Br J Cancer

.

2008

;

99

(

9

):

1468

–

75

.

101.

Birner

P

,

Jesch

B

,

Friedrich

J

,

Riegler

M

,

Zacherl

J

,

Hejna

M

, .

Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression

.

Ann Surg Oncol

.

2011

;

18

(

12

):

3330

–

7

.

102.

Drenckhan

A

,

Freytag

M

,

Supuran

CT

,

Sauter

G

,

Izbicki

JR

,

Gros

SJ

.

CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target

.

J Enzyme Inhib Med Chem

.

2018

;

33

(

1

):

1024

–

33

.

103.

van Kuijk

SJA

,

Yaromina

A

,

Houben

R

,

Niemans

R

,

Lambin

P

,

Dubois

LJ

.

Prognostic significance of carbonic anhydrase IX expression in cancer patients: a meta-analysis

.

Front Oncol

.

2016

;

6

:

69

.

104.

Becker

HM

.

Carbonic anhydrase IX and acid transport in cancer

.

Br J Cancer

.

2020

;

122

(

2

):

157

–

67

.

105.

Kaluz

S

,

Kaluzova

M

,

Liao

SY

,

Lerman

M

,

Stanbridge

EJ

.

Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show

.

Biochim Biophys Acta

.

2009

;

1795

(

2

):

162

–

72

.

106.

Ma

Z

,

Xiang

X

,

Li

S

,

Xie

P

,

Gong

Q

,

Goh

BC

, .

Targeting hypoxia-inducible factor-1, for cancer treatment: recent advances in developing small-molecule inhibitors from natural compounds

.

Semin Cancer Biol

.

2022

;

80

:

379

–

90

.

107.

Zhang

L

,

Ye

SB

,

Li

ZL

,

Ma

G

,

Chen

SP

,

He

J

, .

Increased HIF-1alpha expression in tumor cells and lymphocytes of tumor microenvironments predicts unfavorable survival in esophageal squamous cell carcinoma patients

.

Int J Clin Exp Pathol

.

2014

;

7

(

7

):

3887

–

97

.

108.

Jing

SW

,

Wang

J

,

Xu

Q

.

Expression of hypoxia inducible factor 1 alpha and its clinical significance in esophageal carcinoma: a meta-analysis

.

Tumour Biol

.

2017

;

39

(

7

):

1010428317717983

.

109.

Shao

N

,

Han

Y

,

Song

L

,

Song

W

.

Clinical significance of hypoxia-inducible factor 1α, and its correlation with p53 and vascular endothelial growth factor expression in resectable esophageal squamous cell carcinoma

.

J Cancer Res Ther

.

2020

;

16

(

2

):

269

–

75

.

110.

Herrmann

GR

,

Vogelpohl

EB

,

Hejtmancik

MR

,

Wright

JC

.

Therapy of hypertension with orally given syrosingopine

.

J Am Med Assoc

.

1959

;

169

(

14

):

1609

–

12

.

111.

Rojas

LBA

,

Gomes

MB

.

Metformin: an old but still the best treatment for type 2 diabetes

.

Diabetol Metab Syndr

.

2013

;

5

(

1

):

6

.

112.

Benjamin

D

,

Robay

D

,

Hindupur

SK

,

Pohlmann

J

,

Colombi

M

,

El-Shemerly

MY

, .

Dual inhibition of the lactate transporters MCT1 and MCT4 is synthetic lethal with metformin due to NAD+ depletion in cancer cells

.

Cell Rep

.

2018

;

25

(

11

):

3047

–

58.e4

.

113.

Granja

S

,

Marchiq

I

,

Le Floch

R

,

Moura

CS

,

Baltazar

F

,

Pouyssegur

J

.

Disruption of BASIGIN decreases lactic acid export and sensitizes non-small cell lung cancer to biguanides independently of the LKB1 status

.

Oncotarget

.

2015

;

6

(

9

):

6708

–

21

.

114.

Kendrick

AA

,

Schafer

J

,

Dzieciatkowska

M

,

Nemkov

T

,

D’Alessandro

A

,

Neelakantan

D

, .

CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogramming

.

Oncotarget

.

2017

;

8

(

4

):

6742

–

62

.

115.

Dana

P

,

Saisomboon

S

,

Kariya

R

,

Okada

S

,

Obchoei

S

,

Sawanyawisuth

K

, .

CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion

.

Cell Oncol

.

2020

;

43

(

2

):

211

–

22

.

116.

Maacha

S

,

Hong

J

,

von Lersner

A

,

Zijlstra

A

,

Belkhiri

A

.

AXL mediates esophageal adenocarcinoma cell invasion through regulation of extracellular acidification and lysosome trafficking

.

Neoplasia

.

2018

;

20

(

10

):

1008

–

22

.

117.

Kim

HK

,

Lee

I

,

Bang

H

,

Kim

HC

,

Lee

WY

,

Yun

SH

, .

MCT4 expression is a potential therapeutic target in colorectal cancer with peritoneal carcinomatosis

.

Mol Cancer Ther

.

2018

;

17

(

4

):

838

–

48

.

118.

Todenhofer

T

,

Seiler

R

,

Stewart

C

,

Moskalev

I

,

Gao

J

,

Ladhar

S

, .

Selective inhibition of the lactate transporter MCT4 reduces growth of invasive bladder cancer

.

Mol Cancer Ther

.

2018

;

17

(

12

):

2746

–

55

.

119.

Guan

X

,

Rodriguez-Cruz

V

,

Morris

ME

.

Cellular uptake of MCT1 inhibitors AR-C155858 and AZD3965 and their effects on MCT-mediated transport of L-lactate in murine 4T1 breast tumor cancer cells

.

AAPS J

.

2019

;

21

(

2

):

13

.

120.

Miranda-Goncalves

V

,

Goncalves

CS

,

Granja

S

,

Vieira de Castro

J

,

Reis

RM

,

Costa

BM

, .

MCT1 is a new prognostic biomarker and its therapeutic inhibition boosts response to temozolomide in human glioblastoma

.

Cancers

.

2021

;

13

(

14

):

3468

.

121.

Amorim

R

,

Pinheiro

C

,

Miranda-Goncalves

V

,

Pereira

H

,

Moyer

MP

,

Preto

A

, .

Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells

.

Cancer Lett

.

2015

;

365

(

1

):

68

–

78

.

122.

Baltazar

F

,

Valente

D

,

Afonso

J

,

Queirós

O

,

Granja

S

.

Chapter 17: new horizons on pH regulators as cancer biomarkers and targets for pharmacological intervention

. In:

Koltai

T

,

Reshkin

SJ

,

Harguindey

S

, editors.

An innovative approach to understanding and treating cancer: targeting pH

.

Academic Press

;

2020

. p.

417

–

50

.

https://www.clinicaltrials.gov/ct2/show/NCT01791595?term=AZD3965&cond=cancer&draw=2&rank=1

123.

US National Library of Medicine

.

ClinicalTrials.gov.

(accessed May 30, 2021)

.

124.

Halford

SER

,

Jones

P

,

Wedge

S

,

Hirschberg

S

,

Katugampola

S

,

Veal

G

, .

A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours

.

J Clin Oncol

.

2017

;

35

(

15_Suppl l

):

2516

–

6

.

125.

Michels

PAM

,

Michels

JPJ

,

Boonstra

J

,

Konings

WN

.

Generation of an electrochemical proton gradient in bacteria by the excretion of metabolic end products

.

FEMS Microbiol Lett

.

1979

;

5

(

5

):

357

–

64

.

126.

Gatenby

RA

,

Gawlinski

ET

.

A reaction-diffusion model of cancer invasion

.

Cancer Res

.

1996

;

56

(

24

):

5745

–

53

.